Observational Study of Dermatomyositis Using CDASI
This is an observational study at the University of Pennsylvania for people with dermatomyositis (a rare inflammatory disease that affects skin and muscles). Researchers are using a database to better understand the disease, including how it affects your body, your mental well-being, and your quality of life. They are specifically looking at how your skin symptoms respond to treatment over about one year, using a tool called the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). This study aims to gather valuable information from 300 participants to help improve care for dermatomyositis patients.
- Study design
- This is an observational study, meaning researchers will collect information without giving any specific treatments. It involves about 300 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your skin symptoms will be measured through study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Cutaneous Dermatomyositis Disease Area and Severity Indexthrough study completion, an average of 1 year
Disease severity tool